{
    "root": "924196c1-61fe-4825-8ad2-41be1321f0d6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Hycodan",
    "value": "20240109",
    "ingredients": [
        {
            "name": "hydrocodone bitartrate",
            "code": "NO70W886KK"
        },
        {
            "name": "homatropine methylbromide",
            "code": "68JRS2HC1C"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Dibasic Calcium Phosphate Dihydrate",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Starch, Corn",
            "code": "O8232NY3SJ"
        },
        {
            "name": "Stearic Acid",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "anhydrous citric acid",
            "code": "XF417D3PSL"
        },
        {
            "name": "FD&C red no. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "methylparaben",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "CHERRY",
            "code": "BUC5I9595W"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        }
    ],
    "indications": "HYCODAN is indicated for the symptomatic relief of cough in adult patients 18 years of age and older.",
    "contraindications": "Adults 18 years of age and older : One (1) tablet or 5 mL of the oral solution every 4 to 6 hours as needed; not to exceed six (6) tablets or 30 mL in 24 hours. ( 2.2 ) Measure HYCODAN oral solution with an accurate milliliter measuring device. ( 2.1 , 5.5 ) Do not increase the dose or dosing frequency. ( 2.1 ) Prescribe for the shortest duration consistent with treatment goals. ( 2.3 ) Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology. ( 2.3 ) Reevaluate patient prior to refilling. ( 2.3 )",
    "warningsAndPrecautions": "HYCODAN is supplied as a white-colored, biconvex tablet, one face bisected and debossed with \"205\", and the other face plain, available in:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           NDC 64950-205-03\n                           Bottles of 30\n                        \n                        \n                           \n                           NDC 64950-205-10\n                           Bottles of 100\n                        \n                     \n                  \n                  Store tablets at controlled room temperature 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light–resistant container, as defined in the USP, with a child-resistant closure.\n                  HYCODAN is available as a clear red-colored, cherry-flavored oral solution in:\n                  \n                     \n                         NDC 64950-342-05: Unit Dose Cup of 5 mL\n                     \n                         NDC 64950-342-45: Case contains 40 unit dose cups of 5 mL (NDC 64950-342-05), packaged in 4 trays of 10 unit dose cups each\n                     \n                         NDC 64950-342-47: Bottle of 473 mL",
    "adverseReactions": "HYCODAN is contraindicated for:\n                  \n                     All pediatric patients younger than 6 years of age [see Warnings and Precautions (5.2, 5.3), Use in Specific Populations (8.4)].\n                     Significant respiratory depression [see Warnings and Precautions (5.2)].\n                     Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.4)].\n                     Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.9)].\n                     Hypersensitivity to hydrocodone, homatropine, or any of the inactive ingredients in HYCODAN [see Adverse Reactions (6)]."
}